TY - CHAP
T1 - Hematopoietic Cell Transplantation (HCT) for Acute Lymphoblastic Leukemia (ALL)
AU - Poon, Limei Michelle
AU - Kebriaei, Partow
N1 - Publisher Copyright:
© 2021, Springer Nature Switzerland AG.
PY - 2021
Y1 - 2021
N2 - The treatment paradigm for acute lymphomablastic leukemia has been constantly changing. Historically, allogeneic transplantation (alloHCT) has been a mainstay in the treatment for adult ALL patients due to its effectiveness in preventing disease relapse and due to the poorer outcomes of adult ALL treatment protocols compared to pediatric patients. There have been ongoing advances in the treatment of ALL including the use of pediatric-like protocols as well as the incorporation of oncogenomics and MRD-based responses into prognostic models. In addition, in the last decade, there has been a rapid development of immune-based therapies, and three agents inotuzumab, blinatumomab, and chimeric antigenic T-cell therapy (CAR-T) have been approved for the treatment for relapsed ALL. In the field of alloHCT, the use of reduced intensity conditioning and alternative donor sources has improved the accessibility of alloHCT. In this chapter, we review the latest literature addressing these issues and discuss the relevance of alloHCT in this rapidly changing treatment landscape.
AB - The treatment paradigm for acute lymphomablastic leukemia has been constantly changing. Historically, allogeneic transplantation (alloHCT) has been a mainstay in the treatment for adult ALL patients due to its effectiveness in preventing disease relapse and due to the poorer outcomes of adult ALL treatment protocols compared to pediatric patients. There have been ongoing advances in the treatment of ALL including the use of pediatric-like protocols as well as the incorporation of oncogenomics and MRD-based responses into prognostic models. In addition, in the last decade, there has been a rapid development of immune-based therapies, and three agents inotuzumab, blinatumomab, and chimeric antigenic T-cell therapy (CAR-T) have been approved for the treatment for relapsed ALL. In the field of alloHCT, the use of reduced intensity conditioning and alternative donor sources has improved the accessibility of alloHCT. In this chapter, we review the latest literature addressing these issues and discuss the relevance of alloHCT in this rapidly changing treatment landscape.
KW - Acute lymphoblastic leukemia
KW - Allogeneic transplantation
KW - Autologous transplantation
KW - Novel immunotherapy
KW - Ph negative
UR - http://www.scopus.com/inward/record.url?scp=85092652996&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092652996&partnerID=8YFLogxK
U2 - 10.1007/978-3-030-53633-6_13
DO - 10.1007/978-3-030-53633-6_13
M3 - Chapter
AN - SCOPUS:85092652996
T3 - Hematologic Malignancies
SP - 193
EP - 204
BT - Hematologic Malignancies
PB - Springer Science and Business Media Deutschland GmbH
ER -